- |||||||||| Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: BISCAY: Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (clinicaltrials.gov) - Dec 12, 2016
P1b, N=110, Recruiting, Trial primary completion date: May 2018 --> Mar 2019
- |||||||||| Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics, AZD5069 / AstraZeneca
Trial primary completion date, Monotherapy, PD(L)-1 Biomarker, IO biomarker: Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck (clinicaltrials.gov) - Dec 8, 2016 P1b/2, N=147, Recruiting, Trial primary completion date: May 2018 --> Mar 2019 Trial primary completion date: Sep 2017 --> May 2018
- |||||||||| Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
Mismatch repair, PD(L)-1 Biomarker, IO biomarker, dMMR: NCI-2018-01296: Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer (clinicaltrials.gov) - Dec 5, 2016 P2, N=75, Not yet recruiting,
- |||||||||| Biomarker, Enrollment open, PARP Biomarker, PD(L)-1 Biomarker: BISCAY: Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (clinicaltrials.gov) - Oct 26, 2016
P1b, N=110, Recruiting, Trial primary completion date: Sep 2017 --> May 2018 Not yet recruiting --> Recruiting
- |||||||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
Enrollment open, Combination therapy, Monotherapy, PD(L)-1 Biomarker, IO biomarker: MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023) (clinicaltrials.gov) - Jul 22, 2016 P1b, N=186, Recruiting, Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
Phase classification, Combination therapy, Monotherapy, PD(L)-1 Biomarker, IO biomarker: MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023) (clinicaltrials.gov) - Jul 20, 2016 P1b, N=186, Not yet recruiting, Not yet recruiting --> Recruiting Phase classification: P1 --> P1b
- |||||||||| Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics, AZD5069 / AstraZeneca
Phase classification, Monotherapy, PD(L)-1 Biomarker, IO biomarker: Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck (clinicaltrials.gov) - Jun 15, 2016 P1b/2, N=147, Recruiting, Phase classification: P1 --> P1b Phase classification: P1/2 --> P1b/2
- |||||||||| Biomarker, Enrollment open, Phase classification, Enrollment change, PARP Biomarker, PD(L)-1 Biomarker: BISCAY: Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (clinicaltrials.gov) - Jun 11, 2016
P1b, N=110, Recruiting, Phase classification: P1/2 --> P1b/2 Not yet recruiting --> Recruiting | Phase classification: P1 --> P1b | N=40 --> 110
- |||||||||| danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
Enrollment change, Trial termination: AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites (clinicaltrials.gov) - Apr 11, 2016 P2, N=1, Terminated, Not yet recruiting --> Recruiting | Phase classification: P1 --> P1b | N=40 --> 110 N=15 --> 1 | Recruiting --> Terminated; Study was closed because we could not find these types of patients.
- |||||||||| danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
Trial primary completion date, Metastases: Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers (clinicaltrials.gov) - Jan 17, 2016 P1/2, N=80, Active, not recruiting, N=15 --> 1 | Recruiting --> Terminated; Study was closed because we could not find these types of patients. Trial primary completion date: Feb 2015 --> Jul 2016
- |||||||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
Trial initiation date, Trial primary completion date, Combination therapy, Monotherapy, PD(L)-1 Biomarker, IO biomarker: MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023) (clinicaltrials.gov) - Jan 7, 2016 P1, N=186, Not yet recruiting, Trial primary completion date: Feb 2015 --> Jul 2016 Initiation date: Nov 2015 --> Apr 2016 | Trial primary completion date: Dec 2019 --> Apr 2021
- |||||||||| Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics, AZD5069 / AstraZeneca
Trial primary completion date, Monotherapy, PD(L)-1 Biomarker, IO biomarker: Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck (clinicaltrials.gov) - Dec 11, 2015 P1/2, N=147, Recruiting, Initiation date: Nov 2015 --> Apr 2016 | Trial primary completion date: Dec 2019 --> Apr 2021 Trial primary completion date: May 2017 --> Sep 2017
- |||||||||| Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: BISCAY: Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (clinicaltrials.gov) - Oct 22, 2015
P1, N=40, Not yet recruiting, Trial primary completion date: May 2017 --> Sep 2017 Trial primary completion date: Dec 2016 --> Jun 2018
- |||||||||| Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics, AZD5069 / AstraZeneca
Trial primary completion date, Monotherapy, PD(L)-1 Biomarker, IO biomarker: Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck (clinicaltrials.gov) - Oct 1, 2015 P1/2, N=147, Recruiting, Trial primary completion date: Dec 2016 --> Jun 2018 Trial primary completion date: Dec 2016 --> May 2017
- |||||||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
New P1 trial, Combination therapy, Monotherapy, PD(L)-1 Biomarker, IO biomarker: MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023) (clinicaltrials.gov) - Sep 16, 2015 P1, N=186, Not yet recruiting,
- |||||||||| Biomarker, New P1 trial, PARP Biomarker, PD(L)-1 Biomarker: BISCAY: Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (clinicaltrials.gov) - Sep 14, 2015
P1, N=40, Not yet recruiting,
- |||||||||| Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics, AZD5069 / AstraZeneca
Enrollment open, Trial primary completion date, Monotherapy, PD(L)-1 Biomarker, IO biomarker: Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck (clinicaltrials.gov) - Aug 27, 2015 P1/2, N=147, Recruiting, Trial primary completion date: Dec 2016 --> May 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2018 --> Dec 2016
- |||||||||| Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics, AZD5069 / AstraZeneca
New P1/2 trial, Monotherapy, PD(L)-1 Biomarker, IO biomarker: Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck (clinicaltrials.gov) - Jul 16, 2015 P1/2, N=147, Not yet recruiting,
- |||||||||| danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
Enrollment closed, Trial primary completion date, Metastases: A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma (clinicaltrials.gov) - Dec 6, 2014 P1, N=42, Active, not recruiting, Active, not recruiting --> Completed | N=42 --> 58 | Trial primary completion date: Jul 2015 --> Feb 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Jul 2015
- |||||||||| danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
Enrollment closed, Trial primary completion date, Metastases: Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers (clinicaltrials.gov) - Nov 12, 2014 P1/2, N=80, Active, not recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Jul 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Feb 2015
|